Navigation Links
Pharmacyclics Reports Second Quarter 2013 Results
Date:7/31/2013

the quarter ended June 30, 2012. The increase in revenue was primarily due to the Company earning a $50 million milestone payment during the quarter ended June 30, 2013 under its collaboration and license agreement (the "Agreement") with Janssen Biotech, Inc. and its affiliates ("Janssen"). The $50 million milestone was earned on April 11, 2013 as a result of the enrollment of a fifth patient in a study using ibrutinib (PCI-32765) as a monotherapy versus chlorambucil in elderly patients with newly diagnosed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Revenue for the six months ended June 30, 2013 was $57.5 million, compared to $4.1 million for the six months ended June 30, 2012.

To date, the Company has received four milestone payments from Janssen of $50 million each, totaling $200 million, under the Agreement. The Company may receive up to an additional $625 million ($50 million for development progress, $225 million for regulatory progress, and $350 million for regulatory approval) in development and regulatory milestone payments, however, clinical development entails risks and the Company has no assurance as to whether or when the milestone targets might be achieved.

The Agreement with Janssen includes a cost sharing arrangement for certain development activities. In general, Janssen is responsible for approximately 60% of development costs and the Company is responsible for 40% of development costs. The Agreement with Janssen also provides for a $50 million annual cap of the Company's share of development costs and pre-tax commercialization losses for each calendar year.

GAAP operating expenses were $42.7 million for the quarter ended June 30, 2013, compared to $19.6 million for the quarter ended June 30, 2012. During the three months ended June 30, 2013, the Company exceeded the $50 million annual cap on the Company's share of development costs and pre-tax commercialization losses by $20.4 million. The Company reco
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
2. Pharmacyclics Reports First Quarter 2013 Results
3. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
4. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
5. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
6. Pharmacyclics, Inc. Prices Public Offering of Common Stock
7. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
8. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
9. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
10. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 2015   NineSigma the leading innovation partner to ... estimated overall revenue growth and anticipates the creation of over ... Open Innovation Incentive (OII). In 2013, the ... of over $2 million to accelerate adoption of open innovation ... and $1 Billion in revenues. To date over 45 middle ...
(Date:8/27/2015)... , Aug. 27, 2015  Generex Biotechnology Corporation ... of a white paper on the status of Generex ... white paper was presented to the August 19, 2015 ... James H. Anderson, Jr. , MD, the Company,s Chief ... on the Generex website. The white paper ...
(Date:8/27/2015)... Calif. , Aug. 27, 2015  Mytrus, a technology and ... software platform for electronic informed consent has received approval ... Health Service (NHS). It is the first time e-Consent ... England . Mytrus was ... use in a clinical trial by the U.S. Food ...
Breaking Medicine Technology:State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 2State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 3Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 5Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 6Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 7
... Corporation today,announced that it is seeking 510(k) authorization ... use of its FluDetect(R) Avian Influenza Virus,rapid test ... into the,human point-of-care diagnostic marketplace. While it is ... to the human field, it is,actively seeking an ...
... In Children,s DNA, a Hint of a Mutation,s Ancestral ... researchers,seeking to replicate another group,s discovery of an important ... a particular,variant in DNA that may be more helpful ... populations worldwide. The finding suggests that,the gene variant, identified ...
Cached Medicine Technology:Synbiotics Corporation Announces Human Submission for FluDetect(R) 2Gene Hunters Fine-Tune Marker for Common Obesity Gene 2Gene Hunters Fine-Tune Marker for Common Obesity Gene 3
(Date:8/28/2015)... St. Louis, MO (PRWEB) , ... August 28, ... ... defendants in testosterone lawsuits now consolidated as MDL 2545, Testosterone Replacement ... establishment of a cap on the number of custodial files the PSC may ...
(Date:8/28/2015)... ... 28, 2015 , ... A complimentary webinar offered by healthcare consulting and accounting ... proposal to mandate bundled payments through the Comprehensive Care for Joint Replacement ... Comprehensive Care for Joint Replacement,” takes place at 12 noon EDT on Wednesday, September ...
(Date:8/28/2015)... ... ... Super-Sod launched their new website this summer. The new user-friendly site has ... web design. Website users will now have an improved browsing experience on their phones, ... for the monthly turf-tips email, and find a local Super-Sod store all from the ...
(Date:8/28/2015)... ... 2015 , ... Where can successful, well educated, or attractive ... up to help quality singles find dating partners or ideal matches. , ... well educated, or attractive. , It updates profiles under the category of " ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... through health promotion and disease prevention, improving a patient’s quality of life through ... the community, including heart disease, cancer, diabetes, HIV/AIDS, STDs, and others. A Women’s, ...
Breaking Medicine News(10 mins):Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 3Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 4Health News:PYA Offers Complimentary CCJR Webina — Game On 2Health News:PYA Offers Complimentary CCJR Webina — Game On 3Health News:MillionaireMatchmakerOnline.net Collects and Updates Newest Millionaire and Quality Single Profiles on the Page of Millionaire Matchmaker Online Canada. 2Health News:MillionaireMatchmakerOnline.net Collects and Updates Newest Millionaire and Quality Single Profiles on the Page of Millionaire Matchmaker Online Canada. 3Health News:Health Clinic Opening and Public Art Unveiling 2
... non-cancerous breast disease, study finds , MONDAY, April 12 (HealthDay ... the chances that they will develop non-cancerous breast disease in ... Research published online April 12 in the journal Pediatrics ... their teen years -- daily or nearly every day -- ...
... to support the fact that smoking in cars is 23 ... analysis article in CMAJ ( Canadian Medical Association ... article, by Australian researchers, describes how a local media report ... times more toxic in a vehicle than in a home"" ...
... of air pollutants, especially nitrogen dioxide, has been associated ... in vitro fertilization, according to a team of fertility ... the first pregnancy attempt of 7,403 women undergoing IVF ... Pa.; Shady Grove Fertility, Rockville, Md.; and Columbia University ...
... Girls and young women who drink alcohol increase their ... by researchers at Washington University School of Medicine in ... the risk for developing breast cancer. "Our study ... increased with the amount of alcohol consumed in this ...
... COLUMBUS, Ohio Most women scheduled for gynecologic surgery to ... they were not worried about the effects of the procedure ... of women planning to be sterilized did express concern in ... the operation even though that surgery does not affect ...
... ... helps women improve body image and boost confidence in time for summer with laser hair ... ... many women, spring ushers in the season of renewed commitment to diet and exercise in ...
Cached Medicine News:Health News:Teen Drinking May Boost Breast Problems Later 2Health News:Teen Drinking May Boost Breast Problems Later 3Health News:Second-hand smoke toxicity in cars: Myth into fact 2Health News:Exposure to nitrogen dioxide lowers in vitro fertilization success 2Health News:Adolescent drinking adds to risk of breast disease, breast cancer 2Health News:Most women facing gynecologic surgery don't worry about its effects on sex 2Health News:Most women facing gynecologic surgery don't worry about its effects on sex 3Health News:Most women facing gynecologic surgery don't worry about its effects on sex 4Health News:Epione Helps Women Get Ready for Bikini Season without Hitting the Gym 2Health News:Epione Helps Women Get Ready for Bikini Season without Hitting the Gym 3
Open wire loops decrease the chance of interfering with instruments, Designed to retract the eyelid during ophthalmic microsurgery or minor office procedures...
Blunt, round tip facilitates easier separation of the nucleus. 45 6.0mm from tip, Blunt, Angled, 6.0mm from tip, 1.5mm from end...
Unique 2 in 1 design allows simultaneous absorption of excess fluid & protection of flap & hinge, Lint-free PVAmaterial....
Smaller diameter wire probes & olive shape tips provide easier insertion through the lacrimal sac, 35cm (14 in) long, ID- .30mm (.012in); OD- .64mm (.025 in). S.S. Probes: .40mm x 11cm (27 G x 4 1/4...
Medicine Products: